Biogen Inc. (BIIB)

332.03
NASDAQ : Health Technology
Prev Close 332.03
Day Low/High 0.00 / 0.00
52 Wk Low/High 249.17 / 388.67
Avg Volume 1.30M
Exchange NASDAQ
Shares Outstanding 201.48M
Market Cap 68.01B
EPS 11.90
P/E Ratio 21.85
Div & Yield N.A. (N.A)
Davos, Caterpillar, Intel, Ford and Kroger - 5 Things You Must Know

Davos, Caterpillar, Intel, Ford and Kroger - 5 Things You Must Know

U.S. stock futures rise as the dollar plunges to a fresh three-year low. Caterpillar, Intel and 3M leading the earnings calendar.

Biogen Reports Record Revenues For Both The Full Year And Fourth Quarter Of 2017, $12.3 Billion And $3.3 Billion, Respectively

Biogen Reports Record Revenues For Both The Full Year And Fourth Quarter Of 2017, $12.3 Billion And $3.3 Billion, Respectively

Biogen Inc. (Nasdaq: BIIB) today reported full year and fourth quarter 2017 financial results, including: Full year total revenues of $12.

Tax Reform's Impact on the Economy

Tax Reform's Impact on the Economy

Consumer spending should be more than solid given wage increases.

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.

Jim's Daily Rundown

In today's video, Jim discusses the government shutdown, an Eli Lilly downgrade, Schlumberger after Friday's earnings, and several other market-related topics.

Shutdown Enters Day 3, Sanofi Buys Bioverativ - 5 Things You Must Know

Shutdown Enters Day 3, Sanofi Buys Bioverativ - 5 Things You Must Know

U.S. stock futures suggest Wall Street will open lower on Monday, as investors watch for the impact of a federal government shutdown that has extended into its third day.

Sanofi Strikes $11.6 Billion Deal for Bioverativ

Sanofi Strikes $11.6 Billion Deal for Bioverativ

France's Sanofi could end its long search for a biotech deal after striking an $11.6 billion offer for Massachusetts-based Bioverativ, a maker of hemophilia treatments.

Biogen To Report Fourth Quarter And Year-End 2017 Financial Results On January 25, 2018- Updated Call Timing

Biogen To Report Fourth Quarter And Year-End 2017 Financial Results On January 25, 2018- Updated Call Timing

Biogen Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2017 financial results on Thursday, January 25, 2018, before the financial markets open.

Jim Cramer: Stocks Are on Fire For Good Reasons

Jim Cramer: Stocks Are on Fire For Good Reasons

Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

Biogen Becomes #205 Most Shorted S&P 500 Component, Replacing Vulcan Materials

Biogen Becomes #205 Most Shorted S&P 500 Component, Replacing Vulcan Materials

The most recent short interest data has been released for the 12/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Stocks Close Higher as Wall Street Dissects New Tax Laws

Stocks Close Higher as Wall Street Dissects New Tax Laws

Major indexes held gains Thursday following passage of a $1.5 trillion U.S. tax bill that will slash corporate taxes.

Biogen To Report Fourth Quarter And Year-End 2017 Financial Results On January 25, 2018

Biogen To Report Fourth Quarter And Year-End 2017 Financial Results On January 25, 2018

Biogen Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2017 financial results on Thursday, January 25, 2018, before the financial markets open.

Biogen And Ionis Enter Into New Collaboration To Identify Novel Therapies For The Treatment Of Spinal Muscular Atrophy

Biogen And Ionis Enter Into New Collaboration To Identify Novel Therapies For The Treatment Of Spinal Muscular Atrophy

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of...

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Biogen To Present At The 36th Annual J.P. Morgan Healthcare Conference

Biogen To Present At The 36th Annual J.P. Morgan Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 36 th Annual J.

4 Signs the Bull Market in Stocks Remains Incredibly Strong

4 Signs the Bull Market in Stocks Remains Incredibly Strong

Growth is here to stay, and value is for more than just the old strongholds.

Biogen To Present At The Guggenheim 5th Annual Healthcare Conference

Biogen To Present At The Guggenheim 5th Annual Healthcare Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Guggenheim 5 th Annual Healthcare Conference.

Biogen Appoints Mark Hernon As SVP, Chief Information Officer

Biogen Appoints Mark Hernon As SVP, Chief Information Officer

Biogen (NASDAQ: BIIB) announced today the appointment of Mark Hernon as Senior Vice President, Chief Information Officer, effective December 4.

Biogen Moves Up In Analyst Rankings, Passing Kraft Heinz

Biogen Moves Up In Analyst Rankings, Passing Kraft Heinz

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Biogen Inc has taken over the #96 spot from Kraft Heinz Co , according to ETF Channel. Below is a chart of Biogen Inc versus Kraft Heinz Co plotting their respective rank within the S&P 500 over time (BIIB plotted in blue; KHC plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.

Http://www.alkermes.com/

Http://www.alkermes.com/

Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl...

Biogen And Alkermes Announce License And Collaboration Agreement To Develop And Commercialize ALKS 8700 For The Treatment Of Multiple Sclerosis

Biogen And Alkermes Announce License And Collaboration Agreement To Develop And Commercialize ALKS 8700 For The Treatment Of Multiple Sclerosis

Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl...

Biogen Appoints Jeff Capello As Executive Vice President And Chief Financial Officer

Biogen Appoints Jeff Capello As Executive Vice President And Chief Financial Officer

Biogen (Nasdaq: BIIB) announced today the appointment of Jeffrey D.

Biogen To Present At The Evercore ISI Biopharma Catalyst/Deep Dive Conference

Biogen To Present At The Evercore ISI Biopharma Catalyst/Deep Dive Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference.

Biogen Appoints Chirfi Guindo As Executive Vice President And Head Of Global Marketing, Market Access And Customer Innovation

Biogen Appoints Chirfi Guindo As Executive Vice President And Head Of Global Marketing, Market Access And Customer Innovation

Biogen (Nasdaq: BIIB) announced today the appointment of Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation.

Biogen Presents New Data From Long-Term Extension Of Phase 1b Study Of Investigational Alzheimer's Disease Treatment Aducanumab

Biogen Presents New Data From Long-Term Extension Of Phase 1b Study Of Investigational Alzheimer's Disease Treatment Aducanumab

Biogen (NASDAQ: BIIB) will present new data from the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company's investigational treatment for Alzheimer's disease, at the Clinical Trials on...

The New England Journal Of Medicine Publishes First Phase 3 Study Results Of SPINRAZA® For The Treatment Of Spinal Muscular Atrophy

The New England Journal Of Medicine Publishes First Phase 3 Study Results Of SPINRAZA® For The Treatment Of Spinal Muscular Atrophy

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the end of study results from ENDEAR, the Phase 3 study of SPINRAZA ® (nusinersen) for the treatment of spinal muscular atrophy...

Biogen To Present At The Clinical Trials On Alzheimer's Disease Conference

Biogen To Present At The Clinical Trials On Alzheimer's Disease Conference

Biogen Inc. (NASDAQ: BIIB) announced today that it will present detailed data from a recently conducted analysis of the long-term extension of its ongoing Phase 1b study of aducanumab at the 10 th Clinical Trials on...

TheStreet Quant Rating: B+ (Buy)